ATRX and glioblastoma: However, since the EXTEND signature was developed by comparing pTERTmt samples (OD and GBM) versus ATRX/DAXX altered samples (mostly astrocytomas), it may reflect tumor cell origin/entity rather than TMM status, as demonstrated by Nonneville et al. [25].